Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

M. J. Kerin; P. Gillen; J. R.T. Monson; Jane Wilkie; F. B.V. Keane; W. A. Tanner

doi:10.1016/S0748-7983(95)97305-2

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

M. J. Kerin
, P. Gillen
, J. R.T. Monson
, Jane Wilkie
, F. B.V. Keane
, W. A. Tanner

The Adelaide Hospital

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

16 Citations (Scopus)

Abstract

This prospective randomized trial evaluated the effect of DTIC and interferon as adjuvant therapy for high risk stage I malignant melanoma in 26 patients. Both groups were well matched for depth of disease, site of melanoma and other prognostic criteria. Like other studies the findings of 2.6 times increased relative risk of mortality in the treatment arm do not support a rationale for adjuvant immuno-chemotherapy even in patients at high risk of recurrence.

Original language	English
Pages (from-to)	548-550
Number of pages	3
Journal	European Journal of Surgical Oncology
Volume	21
Issue number	5
DOIs	https://doi.org/10.1016/S0748-7983(95)97305-2
Publication status	Published - Oct 1995
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

adjuvant therapy
chemotherapy
interferon
malignant melanoma

Access to Document

10.1016/S0748-7983(95)97305-2

Cite this

@article{d70eab3650164e08b00544889cbb9e1e,

title = "Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma",

abstract = "This prospective randomized trial evaluated the effect of DTIC and interferon as adjuvant therapy for high risk stage I malignant melanoma in 26 patients. Both groups were well matched for depth of disease, site of melanoma and other prognostic criteria. Like other studies the findings of 2.6 times increased relative risk of mortality in the treatment arm do not support a rationale for adjuvant immuno-chemotherapy even in patients at high risk of recurrence.",

keywords = "adjuvant therapy, chemotherapy, interferon, malignant melanoma",

author = "Kerin, \{M. J.\} and P. Gillen and Monson, \{J. R.T.\} and Jane Wilkie and Keane, \{F. B.V.\} and Tanner, \{W. A.\}",

year = "1995",

month = oct,

doi = "10.1016/S0748-7983(95)97305-2",

language = "English",

volume = "21",

pages = "548--550",

journal = "European Journal of Surgical Oncology",

issn = "0748-7983",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

AU - Kerin, M. J.

AU - Gillen, P.

AU - Monson, J. R.T.

AU - Wilkie, Jane

AU - Keane, F. B.V.

AU - Tanner, W. A.

PY - 1995/10

Y1 - 1995/10

N2 - This prospective randomized trial evaluated the effect of DTIC and interferon as adjuvant therapy for high risk stage I malignant melanoma in 26 patients. Both groups were well matched for depth of disease, site of melanoma and other prognostic criteria. Like other studies the findings of 2.6 times increased relative risk of mortality in the treatment arm do not support a rationale for adjuvant immuno-chemotherapy even in patients at high risk of recurrence.

AB - This prospective randomized trial evaluated the effect of DTIC and interferon as adjuvant therapy for high risk stage I malignant melanoma in 26 patients. Both groups were well matched for depth of disease, site of melanoma and other prognostic criteria. Like other studies the findings of 2.6 times increased relative risk of mortality in the treatment arm do not support a rationale for adjuvant immuno-chemotherapy even in patients at high risk of recurrence.

KW - adjuvant therapy

KW - chemotherapy

KW - interferon

KW - malignant melanoma

UR - https://www.scopus.com/pages/publications/0028875406

U2 - 10.1016/S0748-7983(95)97305-2

DO - 10.1016/S0748-7983(95)97305-2

M3 - Article

C2 - 7589604

AN - SCOPUS:0028875406

SN - 0748-7983

VL - 21

SP - 548

EP - 550

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

IS - 5

ER -

Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this